DVAX DYNAVAX TECHNOLOGIES CORP Insider Trading

President & COO Novack sold 114,000 DVAX shares at $15.64; -64.3% of holdings. Stock up 44.4% in 30d, 54.5% in 90d.

Novack David F, President & COO of Dynavax, sold 114,000 shares (114.0K shares) at $15.64 on 2026-01-15, reducing his stake from 177,344 to 63,344 shares—a -64.3% reduction in holdings. This sale occurs after significant recent appreciation: the stock has gained 44.4% in the prior 30 days and 54.5% over the prior 90 days, placing the transaction price just -0.2% from the 52-week high of $15.72. Notably, all 5 of Novack's prior sales at DVAX were well-timed at the 90-day mark (all showing negative 90-day returns averaging -7.4%), and his cross-ticker track record shows a 100.00% well-timed rate across 5 prior open-market sells with an average 90-day return of -7.7%. The company's fundamentals show strong growth (annual revenue growth of +19.4%, latest quarterly revenue of $94,876,000.00, net income of $26,927,000.00), though the P/E of 74.67 reflects an elevated valuation. The timing—at a 52-week near-high following a 54.5% run-up—combined with this insider's demonstrated pattern of well-timed exits at this ticker warrants investor attention.

Director Myers Scott Dunseth buys 3,800 shares of DVAX at $10.82; stock now -27.8% from 52-week high.

Director Myers Scott Dunseth purchased 3,800 shares at $10.82 on 2025-08-22, increasing his holdings to 35,004 shares. The current price of $10.39 is -27.8% from the 52-week high of $14.40, indicating the purchase occurred near recent lows. However, Dunseth's cross-ticker track record across his open-market activity shows 2 prior buys with an average 90-day return of -19.2% and a 90-day win rate of 0.00%, suggesting this insider's prior buy decisions have not generated positive subsequent returns. Despite the company's solid near-term fundamentals—revenue of $95,442,000.00 with net income of $18,721,000.00 and annual revenue growth of +19.4%—the elevated P/E of 49.48 and the insider's consistent negative post-buy returns warrant investor caution.

10% Owner Deep Track Biotech sells 2,065,137 shares (2.07M) for $22,351,598.19 across two days at $11.03–$10.59

Deep Track Biotechnology Master Fund, Ltd., a 10% holder, executed two separate sales totaling 2,065,137 shares for $22,351,598.19 at a blended average price of $10.82 on August 21–22, 2025, reducing its stake by 11.6% from 17,791,486 to 15,726,349 shares. The fund sold into a price environment where DVAX trades at $10.50 today, -27.1% from its 52-week high of $14.40, and the transaction prices of $11.03–$10.59 sat near the upper end of recent trading—marginally above current levels but below the recent high. Given DVAX's strong fundamentals (19.4% annual revenue growth, positive net income of $18.7M, and a market cap of $1.2B), the sale represents a material reduction in a major stakeholder's conviction, not a forced liquidation or structured plan execution that would suggest indifference to timing. The multi-day execution and substantial size ($22.4M) indicate a deliberate action by an informed holder managing a significant position.